Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone Feasibility in Mild Cognitive Impairment
NCT02878538Phase 1Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Jan 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of deferiprone in Mild Cognitive Impairment (MCI), sponsored by UT Health San Antonio. Primary endpoint: Efficacy of deferiprone therapy on 'd' scores at 12 months. Planned start Jan 2018; status: withdrawn.
02
Drugs
deferiprone
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02878538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878538.